Form 4: Amgen Executive Murdo Gordon Reports Stock and Options Grant

Murdo Gordon, EVP at Amgen, reports the acquisition of stock and options, including restricted stock units (RSUs) and non-qualified stock options (NQSOs).

Summary

• Murdo Gordon, an Executive Vice President at Amgen, filed a Form 4 detailing changes in beneficial ownership of Amgen stock.
• On May 7, 2024, Gordon acquired 3,529 shares of common stock through the grant of Restricted Stock Units (RSUs).
• These RSUs vest in three annual installments starting May 7, 2026.
• Gordon also acquired 22,930 Non-Qualified Stock Options (NQSOs) with an exercise price of $300.30, also granted on May 7, 2024.
• These NQSOs become exercisable on May 7, 2026, and expire on May 7, 2034.
• Following these transactions, Gordon directly owns 52,674 shares of Amgen common stock.
• This total includes previously granted RSUs vesting at various dates in 2025, 2026 and 2027, as well as dividend equivalents (DEs).

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practices, aligning executive interests with shareholder value. There are no explicit negative implications.

Positives

• The grant of RSUs and NQSOs to an executive like Murdo Gordon aligns his interests with the long-term performance of Amgen.
• The vesting schedules of the RSUs (over three years) and the long expiration date of the NQSOs (10 years) encourage sustained commitment.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the granted equity.

Industry Context

Executive compensation in the biopharmaceutical industry often includes stock options and restricted stock units to align executive interests with shareholder value and long-term company performance. This filing reflects a standard practice in the industry.

Comparison to Industry Standards

• Amgen's equity compensation practices are broadly in line with industry standards for large-cap biotechnology companies.
• Companies like Gilead Sciences, Biogen, and Vertex Pharmaceuticals also utilize RSUs and stock options as key components of executive compensation packages.
• The vesting schedules and option terms are typical for incentivizing long-term performance and retention.

Stakeholder Impact

• The equity grants aim to align executive interests with shareholder value, potentially benefiting shareholders through improved company performance.
• The grants serve as an incentive for the executive, potentially improving employee retention and motivation.

Key Dates